Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma

PET Clinics ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. 459-467 ◽  
Author(s):  
Chi Lai Ho ◽  
Sirong Chen ◽  
Shing Kee Cheung ◽  
Thomas Wai Tong Leung
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
18F Fluorodeoxyglucose ◽  
Fluorodeoxyglucose Pet

Diuretic 18F-Fluorodeoxyglucose PET/Computed Tomography in Evaluation of Genitourinary Malignancies

PET Clinics ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. 39-46 ◽  
Author(s):  
Krishan Kant Agarwal ◽  
Shambo Guha Roy ◽  
Rakesh Kumar
Keyword(s):  
Computed Tomography ◽  
18F Fluorodeoxyglucose ◽  
Fluorodeoxyglucose Pet

scholarly journals Clinical Utility of Functional Imaging with 18F-FDOPA in Von Hippel-Lindau Syndrome

2012 ◽  
Vol 97 (4) ◽  
pp. E613-E617 ◽  
Author(s):  
Allison B. Weisbrod ◽  
Mio Kitano ◽  
Krisana Gesuwan ◽  
Corina Millo ◽  
Peter Herscovitch ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Neuroendocrine Tumors ◽  
Clinical Utility ◽  
Laboratory Data ◽  
Imaging Modalities ◽  
Metabolic Imaging ◽  
High Risk Population ◽  
Von Hippel Lindau ◽  
18F Fluorodeoxyglucose ◽  
Fluorodeoxyglucose Pet

Context: Von Hippel-Lindau (VHL) syndrome is an inherited cancer syndrome in which patients are at risk of developing multiple tumors in different organs. 6-L-18F-fluorodihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a relatively new metabolic imaging tracer proposed for the use of localizing sites of neuroendocrine tumors. There are limited data on the clinical utility of using 18F-FDOPA PET for identifying neuroendocrine tumors in a high-risk population such as VHL. Objective: The aim of this prospective study was to evaluate the clinical utility of 18F-FDOPA PET in patients with VHL-related tumors. Design: Radiological findings were prospectively collected from four imaging modalities: computed tomography, magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose PET, and 18F-FDOPA PET. 18F-FDOPA PET findings were compared with those from other imaging modalities, as well as with clinical and laboratory data, and pathology findings if patients underwent an operation. Results: In 52 patients with VHL, 390 lesions were identified by computed tomography (n = 139), MRI (n = 117), 18F-fluorodeoxyglucose PET (n = 94), and 18F-FDOPA PET (n = 40). 18F-FDOPA PET identified 20 pancreatic and 20 extrapancreatic tumors, including lesions in the adrenal gland (n = 11), kidney (n = 3), liver (n = 4), lung (n = 1), and cervical paraganglioma (n = 1). These tumor sites were not seen by conventional imaging studies in 9.6% of patients and 4.4% of lesions. Seven of eight patients who had an 18F-FDOPA PET-positive lesion underwent resection, and pathology showed a neuroendocrine tumor. Four of 10 patients with positive adrenal uptake had elevated catecholamine levels, and six of 10 patients had a discrete mass on axial imaging. Conclusions: 18F-FDOPA PET is a useful complementary imaging study to detect neuroendocrine tumors in patients with VHL undergoing surveillance, especially in those suspected to have adrenal pheochromocytoma or unusual ectopic locations.

Sign in / Sign up

Export Citation Format

Share Document